Last reviewed · How we verify

Sevoflurane/Ultane

Kaohsiung Medical University Chung-Ho Memorial Hospital · FDA-approved active Small molecule

Sevoflurane is a volatile anesthetic that depresses the central nervous system by enhancing inhibitory GABA neurotransmission and inhibiting excitatory glutamate signaling.

Sevoflurane is a volatile anesthetic that depresses the central nervous system by enhancing inhibitory GABA neurotransmission and inhibiting excitatory glutamate signaling. Used for Induction and maintenance of general anesthesia in adults and pediatric patients.

At a glance

Generic nameSevoflurane/Ultane
Also known asSevoflurane/ Ultane 250mL/Bot
SponsorKaohsiung Medical University Chung-Ho Memorial Hospital
Drug classVolatile general anesthetic
TargetGABA-A receptor, NMDA receptor
ModalitySmall molecule
Therapeutic areaAnesthesiology
PhaseFDA-approved

Mechanism of action

Sevoflurane is a halogenated ether that acts as a general anesthetic by modulating multiple ion channels and neurotransmitter receptors in the brain. It enhances the activity of inhibitory GABA-A receptors while simultaneously blocking excitatory NMDA glutamate receptors, resulting in rapid loss of consciousness and anesthesia. The exact molecular mechanisms remain incompletely understood but involve disruption of neuronal signaling at multiple levels.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results